Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vizamyl brain uptake vs post-mortem amyloid
NCT01165554Phase 3Completed
- Sponsor
- GE HealthCare
- Start
- May 2010
- Primary completion
- Nov 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of flutemetamol in Alzheimer's disease (AD), sponsored by GE HealthCare. Started May 2010; status: completed.
02
Drugs
flutemetamol
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT01165554.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01165554.